Scrip is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Quick Listen: Scrip's Five Must-Know Things

Executive Summary

In this week's podcast edition of Five Must-Know Things: Scrip asks what 2022 holds for deal-making; Pfizer looks for transactions to add to its top line; Sanofi unworried about JAK threat to Dupixent; what information do healthcare professionals want from pharma; and Amgen looks to its established brands for growth.

Join us for an audio catch-up on the major events in the biopharma industry over the past business week, as reported by Scrip's global team, in this podcast version of Five Must-Know Things.

This episode covers insights for the business week ended 11 February 2022, including: Scrip asks what 2022 holds for deal-making; Pfizer Inc. looks for transactions to add to its top line; Sanofi unworried about JAK threat to Dupixent; what information do healthcare professionals want from pharma; and Amgen, Inc. looks to its established brands for growth.

This and all our other podcasts are available on the Informa Pharma Intelligence channel on Apple PodcastsGoogle PodcastsSoundCloudTuneIn and Spotify Podcasts, and via smart speakers if one of these platforms has been set up as your default podcast provider.  

Stories mentioned in this episode:

(Also see "Pfizer Shopping For Deals That Will Add $25bn To 2030 Revenues" - Scrip, 9 Feb, 2022.)

(Also see "Sanofi Unruffled By JAK Threat To Dupixent" - Scrip, 4 Feb, 2022.)

(Also see "What Physicians Want: Less of Promotional Content" - Scrip, 7 Feb, 2022.)

(Also see "Amgen’s Growth Story Relies Mainly On Continuing Plot Lines" - Scrip, 8 Feb, 2022.)

Related Content

Topics

Related Companies

Latest News
See All
UsernamePublicRestriction

Register

SC145885

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Thank you for submitting your question. We will respond to you within 2 business days. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel